UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~September 311, 2024

Future Health ESG Corp.

(Exact name of registrant as specified in its charter)

Delaware		001-40788		86-2305680
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

8 The Green, Suite 12081

Dover, DE 19901

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (833) 388-8734

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of common stock and one-half of one redeemable warrant	FHLTU	The Nasdaq Stock Market LLC
Common stock, par value $0.0001 per share	FHLT	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share	FHLTW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~June~~September 311, 2024, Ms. Nikita Jaiswal resigned from the board of directors (the “Board”) ~~made~~of ~~several~~Future ~~key~~Health ~~appointments:~~Esg Corp (the “Company”). The Board duly accepted her resignation. Ms. Jaiswal’s resignation is not due to any disagreements with the Company on any matter relating to the Company’s operations, policies, or practices. The Company will work to rebalance the Board in accordance with Nasdaq Listing Rules as soon as possible.

· Khairul Azmi Bin Ismaon was appointed Chief Executive Officer.

· Dr. Ulf Henning Richter was appointed Chief Financial Officer.

Effective as of June 3, 2024, the Board and the Executive Officers of the Company shall consist of solely the following persons, who shall serve until such person’s successor is elected, qualified, and appointed or until such person’s earlier resignation, removal from office, or death:

Name Title Khairul Azmi Bin Ismaon Chairman, Chief Executive Officer and Director Dr. Ulf Henning Richter Chief Financial Officer Jesvin Kaur Director Nancy Zakhour Independent Director Brian David Kitney Independent Director Nikita Jaiswal Independent Director

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	FUTURE HEALTH ESG CORP
	By:	/s/ Khairul Azmi Bin Ismaon
Date: September 12, 2024	By:	/s/ Khairul Azmi Bin Ismaon
		Name:	Khairul Azmi Bin Ismaon
		Title:	Chief Executive Officer
Date: June 5, 2024

Filing Compare · Future Health ESG Corp.